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Introduction: The US Preventive Services Task Force recommended annual lung cancer 
screening with low-dose computed tomography (LDCT) for high-risk patients in December 
2013. We compared lung cancer screening-related opinions and practices among attending and 
resident primary care physicians (PCPs). 
Methods: In 2015, we conducted a 23-item survey among physicians at a large academic medi-
cal center. We surveyed 100 resident PCPs (30% response rate) and 86 attending PCPs (49% 
response rate) in Family Medicine and Internal Medicine. The questions focused on physicians’ 
opinions, knowledge of recommendations, self-reported practice patterns, and barriers to lung 
cancer screening. In 2015 and 2016, we compared responses among attending versus resident 
PCPs using chi-square/Fisher’s exact tests and 2-samples t-tests.  
Results: Compared with resident PCPs, attending PCPs were older (mean age =47 vs 30 years) 
and more likely to be male (54% vs 37%). Over half of both groups concurred that inconsistent 
recommendations make deciding whether or not to screen difficult. A substantial proportion in 
both groups indicated that they were undecided about the benefit of lung cancer screening for 
patients (43% attending PCPs and 55% resident PCPs). The majority of attending and resident 
PCPs agreed that barriers to screening included limited time during patient visits (62% and 78%, 
respectively), cost to patients (74% and 83%, respectively), potential for complications (53% 
and 70%, respectively), and a high false-positive rate (67% and 73%, respectively). 
Conclusion: There was no evidence to suggest that attending and resident PCPs had differing 
opinions about lung cancer screening. For population-based implementation of lung cancer 
screening, physicians and trainees will need resources and time to address the benefits and 
harms with their patients.
Keywords: lung neoplasms, mass screening, physician behavior, surveys, questionnaires, low 
dose computed tomography, benefits, harms
Introduction
Lung cancer is the leading cause of cancer deaths in the US, resulting in more deaths 
than breast, colorectal, cervical, and prostate cancers combined.1 Since the signs and 
symptoms of lung cancer are nonspecific and do not appear until the disease is advanced, 
the majority of lung cancers are detected at late stages when treatment is less effective and 
survival is poor.2 While randomized controlled trials assessing early lung cancer detec-
tion through screening with conventional radiography failed to find a reduction in lung 
cancer mortality, the National Lung Screening Trial (NLST) showed a 20% reduction in 
lung cancer mortality among current and former heavy smokers who were screened with 
low-dose computed tomography (LDCT) versus chest radiography.3 Despite concerns 
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over the high false-positive rate reported in the NLST and the 
fact that NLST results may not be generalizable to the US 
population as a whole, in December 2013, the US Preventive 
Services Task Force (USPSTF) began recommending annual 
lung cancer screening with LDCT in adults aged 55–80 years 
who are current or former (quit within the past 15 years) 
smokers and have a 30 pack-year smoking history.4 In 2015, 
the Centers for Medicaid and Medicare Services (CMS) began 
covering lung cancer screening with LDCT for those meeting 
the screening criteria; however, the extent to which screening 
practices will change with the new USPSTF recommendation 
and CMS coverage is unknown.5 Approximately 8.7 million 
people in the US meet the NLST criteria of “high risk” (based 
on age and smoking history) and would qualify for screening 
under the USPSTF guidelines.6
Although several groups have endorsed screening,4,7–9 
there is concern that the risk-to-benefit ratio observed in 
the NLST will not translate into real-world settings.10,11 This 
may explain why uptake of lung cancer screening has been 
relatively slow. According to the 2015 National Health Inter-
view Survey, only 3.9% of eligible smokers reported LDCT 
screening in the prior month.12 Understanding the opinions 
and knowledge of published recommendations for lung cancer 
screening among resident and attending primary care physi-
cians (PCPs) are likely to influence implementation of lung 
cancer screening in future years. Prior research has shown 
that physician knowledge of screening guidelines is positively 
correlated with increased utilization of screening procedures.13 
The purpose of this study was to understand and compare 
perceptions of lung cancer screening among attending and 
resident PCPs at one US academic medical center. Specifi-
cally, we explored the relationship between practitioner type 
(attending or resident physician) and screening opinions, 
ordering and referral patterns, and perceived barriers. We 
hypothesized that attending and resident PCPs would both 
report following USPSTF recommendations but that resi-
dent PCPs would perceive more barriers to screening than 
attending PCPs since resident PCPs are more likely to see 
uninsured patients, those with low literacy, and more patients 
with major psychosocial problems than attending PCPs.14,15
Methods
Survey methodology
We designed, pre-tested, and implemented an online survey to 
attending physicians and residents at a single large academic 
medical center using the Tailored Design Method by Dillman 
et al.16 The survey content was developed through collaboration 
with a multidisciplinary Advisory Group comprised of a survey 
methodologist, an epidemiologist and physicians from Internal 
Medicine, Family Medicine, Thoracic Radiology, Pulmonary 
Medicine, and Pathology. A total of 23 survey questions were 
included with a focus on opinions about lung cancer screening, 
recommendations and guidelines for lung cancer screening, 
referral patterns and barriers for lung cancer screening, and 
respondent socio-demographics. Survey questions were com-
prised of Likert scale items, multiple choice, and short answer. 
The survey was administered online, via the Qualtrics software.
We pre-tested the survey among five physicians outside 
of the academic medical center where the survey took place 
to obtain feedback on the survey flow, length, design, and 
ease of understanding and responding to the survey ques-
tions. Based on responses from the pre-testing, we made 
slight modifications to clarify the intent of a few questions.
Through the use of online resources (student service coordi-
nators and department websites), we created a list of 186 poten-
tial Internal and Family Medicine survey respondents. Of these, 
86 (46.2%) were attending physicians and 100 (53.8%) were 
residents. We collected participant names, email addresses, 
and campus box numbers and sent a pre-notification postcard 
in 2015 to each potential participant to introduce the study and 
survey. One week later, we emailed a survey link to each par-
ticipant through Qualtrics. At 1, 5, 8, and 9 weeks post survey 
delivery, we sent reminder emails to the physicians who had 
not yet responded. In addition, we mailed a reminder postcard 
2 weeks after survey deployment. Participation for the study 
was determined by return of the survey. Those who participated 
in the study were given the opportunity to enter into a random 
drawing for an iPad incentive, as offering an incentive has been 
shown to increase response rates for physicians.17–19 Responses 
from returned surveys were stored within the Qualtrics system 
and exported upon survey closure. This study was reviewed and 
approved by the University of North Carolina at Chapel Hill 
Institutional Review Board (Study #13-2672). 
Statistical analyses
We describe the characteristics and responses of the survey 
by attending and resident physicians. We compare survey 
responses between these groups with a 2-sample t-test using 
the Satterthwaite approximation for unequal variances for 
continuous outcomes and chi-square or Fisher’s exact tests for 
categorical outcomes, depending on the expected cell size. All 
analyses were performed in 2015 and 2016 using SAS v9.4.  
Results
Sociodemographic characteristics of the 
attending and resident PCPs
A total of 72 attending and resident PCPs responded to the 
survey for an overall response rate of 38.7%. The response 
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Note: *Percentages are among those with non-missing data.
Table 2 (Continued)
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Notes: aChi-square test or Fisher’s exact test. *Percentages are among those with 
non-missing data.
Table 2 Provider attitudes about lung cancer screening, by 
provider type
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they were convinced that screening for lung cancer is ben-
eficial for patients, 42.5% of attending and 55.2% of resi-
dent physicians were undecided, with a similar proportion 
agreeing or strongly agreeing with the statement (40% vs 
rate was significantly higher for attending PCPs (response 
rate = 42/86 = 48.8%) than for resident PCPs (response rate = 
30/100 =30.0%), p-value =0.01. Attending physicians were 
older with more years in clinical practice and more patients 
were seen per week in the clinic compared with resident 
physicians (Table 1).
Physicians were asked their opinions about screening 
patients for lung cancer (Table 2). When asked whether 
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34.5% respectively). In both physician groups, the majority 
of respondents agreed or strongly agreed that inconsistent 
recommendations about lung cancer screening make it dif-
ficult to decide whether or not to screen (56.1% attending 
vs 65.5% resident). The majority of attending (60.0%) and 
resident PCPs (62.1%) agreed or strongly agreed that they 
had enough knowledge to explain the pros and cons of lung 
cancer screening to patients. More than half of attending and 
resident PCPs agreed or strongly agreed (61.6% and 75.9%, 
respectively) that time restrictions during patient visits result 
in other problems having higher priority than screening for 
lung cancer. 
We asked physicians about the initiation of lung cancer 
screening discussions, as well as ordering and referral prac-
tices during the 12 months prior to the survey to ascertain 
the extent to which these were occurring (Table 3). While 
37.1% of attending physicians reported that patients asked 
whether they should be screened for lung cancer, only 
18.5% of resident physicians reported that patients asked 
about lung cancer screening. The majority of the attending 
(66.7%) and resident (57.1%) physicians reported initiating 
discussion of the risks and benefits of lung cancer screening 
with patients, with a smaller proportion reporting ordering 
LDCT screening (46.2% of attending and 34.5% of resident 
physicians). Approximately 53% of attending and 32% of 
resident physicians reported discussing results of LDCT lung 
cancer screening with the patients. 
Physicians were also asked about perceived barriers to 
recommending lung cancer screening (Table 4). Overall, 
most attending and resident physicians selected at least one 
barrier. In both attending and resident groups, cost to the 
patient was the most cited concern (72.8% vs 83.3%, respec-
tively). Physicians were also concerned with too many false 
positives, potential for complications, potential for emotional 
harm, and cost to the health care system. Less than 15% of 
physicians reported false negatives/missed cancers as a bar-
rier to screening. 
Discussion
We found no evidence to suggest that attending and resident 
PCPs in one large academic medical center share dissimilar 
reservations about the benefits, risks, and barriers associated 
with lung cancer screening with LDCT. Differences between 
attending and resident PCPs may indeed exist, but were not 
detectable given our sample size. The survey developed and 
pilot tested in this study should be conducted in a larger 
population to allow for more in-depth analyses.
Although resident PCPs typically see patients who are 
less likely to have private insurance and more likely to 
Table 3 Lung cancer screening discussion, ordering, and referral 
by provider type
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Table 4 Provider reported barriers to lung cancer screening by 
provider type
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Cost to patient
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have comorbidities than attending physicians,14,15 our sur-
vey results indicated no difference in terms of barriers to 
screening among resident and attending PCPs. Both types 
of physicians reported being unsure of the benefits of lung 
cancer screening and cited many concerns about screen-
ing. Regardless of resident or attending status, respondents 
identified inconsistent recommendations, time restrictions 
during visits, cost to patients, potential complications, and a 
high false-positive rate as barriers to lung cancer screening. 
While more than half of physicians initiated discussions 
about the risks and benefits of lung cancer screening, of 
these, approximately two-thirds of physicians reported 
ordering an LDCT scan and 15%–38% reported referring 
their patient to another provider for further evaluation for 
screening.
Prior to the USPSTF guidelines being released in Decem-
ber 2013, several studies examined provider practices around 
lung cancer screening with sputum cytology, chest radiog-
raphy, or LDCT.13,20–22 These studies found that US PCPs’ 
beliefs and recommendations regarding lung cancer screen-
ing were inconsistent with guidelines20 and that providers 
frequently ordered screening tests even though they were not 
recommended by expert groups.21 Another study conducted 
telephone focus groups with 28 US PCPs and identified 
factors influencing physicians’ decisions to screen, includ-
ing perceptions of the test effectiveness, attitudes toward 
recommended guidelines, practice experience, perceptions 
of the patient’s lung cancer risk, cost of screening, concerns 
about litigation, and patient request for screening.22 An 
additional study was conducted after the results of the NLST 
were published, during the time when some professional 
society guidelines endorsed LDCT but prior to the release of 
updated USPSTF guidelines. This study found that providers 
ordered radiography for lung cancer screening more often 
than LDCT (21% vs 12%, respectively).13 Providers in this 
study also cited that the most common barriers to screening 
included cost to the patient, false-positive findings, patients’ 
lack of awareness, incidental findings, and insurance cover-
age.13 Our finding that over half of respondents agreed that 
inconsistent  recommendations about lung cancer screening 
make it difficult to decide whether or not to screen is likely 
reflective of the fact that the American Academy of Family 
Physicians does not currently endorse lung cancer screen-
ing and that 51% of our respondents are from the Family 
Medicine Department.
Several studies on provider attitudes about lung cancer 
screening have been conducted since the USPSTF recommen-
dation was published.23–26 Two of these focused on specialist 
physicians25,26 while the other two focused on PCPs.23,24 
Hoffman et al conducted semi-structured interviews with 
10 New Mexico PCPs in 2014.19 None of the 10 PCPs had 
screened with LDCT and viewed the NLST results with 
skepticism, particularly the high false-positive rate, the high 
number needed to screen to prevent one lung cancer death, 
and the low enrollment of minority participants. Potential 
barriers noted in this study were following up on abnormal 
tests, concern that New Mexico lacked the infrastructure 
to support high-quality screening programs as required by 
guidelines, challenges of screening rural patients in terms of 
available technology and travel burdens for patients, costs for 
follow-up testing, overloading a primary care system that is 
already taxed, and competing demands during the patient 
visit. In the other study of PCPs, Ersek et al distributed a 
32-item questionnaire via email to all active South Carolina 
Academy of Family Physicians and via paper form to a subset 
of physicians at a meeting in 2015.23 Among the 101 physi-
cians who responded, the majority reported that screening 
with LDCT increased the odds of detecting disease at earlier 
stages and that the benefits outweighed the harms. In the 
prior 12 months, 47% of PCPs had not referred a patient for 
LDCT and some PCPs continued to recommend chest radi-
ography for screening. Concerns about screening included 
unnecessary diagnostic procedures, psychological harms, 
and exposure to radiation.
The results of our physician survey have some similari-
ties and differences to the Hoffman and Ersek studies. First, 
the proportion of respondents in our survey who agreed or 
strongly agreed that lung cancer screening is beneficial for 
patients was lower than that in the South Carolina group 
(35%–40% versus 75%). Second, unlike the South Carolina 
study in which 31% of respondents agreed or strongly agreed 
that LDCT screening is cost-effective, only 6.9% of residents 
and 19.5% of attending PCPs in our study perceived lung can-
cer screening as being cost-effective. Similar to the Hoffman 
study, cost to patients was the most frequently reported barrier 
to lung cancer screening among our respondents. While lung 
cancer screening with LDCT is covered by most of the insur-
ance plans for those patients meeting the high-risk definition, 
the work-up of pulmonary nodules or incidental findings will 
likely incur out-of-pocket expenses for the patient. Third, 
providers in all three studies raised concern about the high 
false-positive rate. In a retrospective analysis, application of 
the American College of Radiology Lung-RADS to NLST 
data suggests that use of Lung-RADS may potentially reduce 
the false-positive rates,27 which may alleviate some provider 
concerns about false positives in the future. 
Powered by TCPDF (www.tcpdf.org)
                               1 / 1






Since our study was conducted at a single US academic 
medical center, our results are limited in generalizability to 
other similar settings. As a safety net system, our institution 
serves a diverse patient population, and the concerns that 
physicians raised about screening are likely reflective of the 
potential burden that would be placed on these patients. By 
asking physicians about their ordering and referral patterns, 
we rely on their reporting, and thus, responses are subject 
to recall bias. In addition, our sample was underpowered to 
detect small differences between attending and resident physi-
cians. There is also the potential for nonresponse bias given 
our overall response rate of 38.7%. This nonresponse bias 
may differentially impact the attending and resident physician 
groups, as the response rates were significantly different for 
the two. We are unable to ascertain whether those who did 
not respond to the survey differed in a systematic way than 
those who did respond. Where feasible, future studies should 
address nonresponse bias by collecting information from 
non-respondents. Where this is impossible, future studies 
should include auxiliary data on the sampling frame in order 
to derive nonresponse adjustments.
Conclusion
Findings from our study suggest that attending and resident 
physicians have similar opinions, ordering and referral pat-
terns, or perceived barriers for lung cancer screening with 
LDCT. Both attending and resident PCPs reported being 
undecided on the utility of screening, and while they report 
having the knowledge to explain the pros and cons of screen-
ing, they do not have enough time during the clinical visit to 
adequately discuss screening. For lung cancer screening to 
be implemented at the population level, physicians will need 
resources and time to fully address the benefits and harms 
of screening with their patients. Furthermore, US attending 
and resident PCPs may need more evidence on the benefits 
of lung cancer screening and its impact on patients in real-
world settings.
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